The company's commitment to advancing human potential through science is evident in its transformative approach and a diverse portfolio of specialized technologies, aiming to accelerate life sciences and diagnostics.

Brand Unveiling and Product Launches

Revvity will debut its new brand, reinforcing its dedication to pushing the boundaries of human potential through scientific innovation. Among the highlights is the launch of the LabChip® AAV empty/full characterization solution, a fast, reliable, and scalable technique for adeno-associated virus (AAV) analysis. This solution streamlines gene therapy development and manufacturing, demonstrating Revvity's commitment to progress in the life sciences.

Innovation in Focus

In response to the evolving personalized medicine landscape, Revvity emphasizes providing high-value, cutting-edge solutions to foster scientific innovation and positively impact human health. Dr. Alan Fletcher, Senior Vice President of Life Sciences at Revvity, expressed, "Our approach and products are centered around assisting scientists in discovering more and translating faster in clinical development, drug discovery, and basic research."

Highlights at SLAS2024

Revvity will showcase a range of life sciences and diagnostics products and services at SLAS2024:

1. New Modalities: Featuring Pin-point™ base editing, AAV engineering and optimization, LentiBOOST® GMP-grade transduction enhancer, and LabChip® AAV empty/full characterization solution.

2. Automation Technologies: Integrated robotics and software solutions for increased productivity, including chemagic™ 360 nucleic acid extraction system, Explorer™ G3 workstation, FlexDrop™ iQ™ non-contact dispenser, and Omni™ LH 96 automated homogenization workstation.

3. Cellular Technologies: Advanced tools for cell analysis, including Cellaca® PLX image cytometry system, Opera Phenix® HCS system, Signals Image Artist™ software, CRISPR, RNAi reagents, and BioLegend® antibodies for flow cytometry.

4. Omics: Comprehensive platforms for accelerated multiomic discoveries, such as single cell proteogenomic assays and Omni™ Bead Ruptor™ solution for tissue homogenization.

5. Precision Medicine and Diagnostics: Tailored diagnostic-enabling and discovery technologies, covering BioLegend® reagents, BioQule™ NGS system, CDX assay development services, ELISPOT® secreted protein detection assays, and MojoSort™ magnetic cell separation system.

6. Assay Development: Advanced solutions to increase assay throughput and precision, including Dharmacon® reagents, no-wash immunoassays, and detection and cellular imaging portfolios featuring EnVision® Nexus™ Multimode microplate reader and IVIS® and Vega® in vivo imaging platforms.

Revvity's presence at SLAS2024 reflects its dedication to scientific advancement, efficiency in drug development, and innovation from early-phase research to clinical applications.